C07K 2317/52
Constant or fc region
Official title: Constant or Fc region; Isotype
C07K2317/52 (Constant or fc region) appears on 4,722 US grants and 10,215 published applications in this corpus.
Search patents in C07K- Granted patents
- 4,722
- Published applications
- 10,215
- Assignees
- 2,294
- Inventors
- 14,917
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 9 | 0 |
| 2001 | 12 | 11 |
| 2002 | 5 | 19 |
| 2003 | 13 | 53 |
| 2004 | 13 | 41 |
| 2005 | 15 | 72 |
| 2006 | 23 | 94 |
| 2007 | 21 | 119 |
| 2008 | 31 | 87 |
| 2009 | 42 | 138 |
| 2010 | 81 | 167 |
| 2011 | 75 | 166 |
| 2012 | 96 | 191 |
| 2013 | 112 | 238 |
| 2014 | 146 | 301 |
| 2015 | 175 | 334 |
| 2016 | 210 | 478 |
| 2017 | 252 | 533 |
| 2018 | 270 | 537 |
| 2019 | 323 | 581 |
| 2020 | 357 | 695 |
| 2021 | 381 | 799 |
| 2022 | 386 | 846 |
| 2023 | 388 | 864 |
| 2024 | 432 | 1060 |
| 2025 | 517 | 1024 |
| 2026 | 320 | 767 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Compositions and methods for modulating FLRT3 mediated signal transduction6 Oct 2026US 12,753,229 B2Nextcure, Inc.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Cd3 binding molecules8 Oct 2026US 2026/0308254 A1Merus N.V.
- Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor8 Oct 2026US 2026/0308257 A1Agenus Inc.
- Agents that bind to cd16a and uses thereof8 Oct 2026US 2026/0308258 A1Avantgen, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,541US 5,661,016 AGenPharm International, Inc. · 1997